These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37690312)

  • 21. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials.
    Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N
    J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
    Chang JS; Ahn YM; Park HJ; Lee KY; Kim SH; Kang UG; Kim YS
    J Clin Psychiatry; 2008 May; 69(5):720-31. PubMed ID: 18370574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Di Nardo F; Santoro V; Spina E; Zoccali RA
    Schizophr Res; 2011 Apr; 127(1-3):93-9. PubMed ID: 21262565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
    Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
    Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial.
    Prasad KM; Eack SM; Keshavan MS; Yolken RH; Iyengar S; Nimgaonkar VL
    Schizophr Bull; 2013 Jul; 39(4):857-66. PubMed ID: 22446565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.
    Kantrowitz JT; Javitt DC; Freedman R; Sehatpour P; Kegeles LS; Carlson M; Sobeih T; Wall MM; Choo TH; Vail B; Grinband J; Lieberman JA
    Neuropsychopharmacology; 2020 Jul; 45(8):1339-1345. PubMed ID: 32015461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia.
    Minzenberg MJ; Yoon JH; Cheng Y; Carter CS
    Neuropsychopharmacology; 2016 Apr; 41(5):1231-40. PubMed ID: 26329382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion.
    Ma TM; Abazyan S; Abazyan B; Nomura J; Yang C; Seshadri S; Sawa A; Snyder SH; Pletnikov MV
    Mol Psychiatry; 2013 May; 18(5):557-67. PubMed ID: 22801410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.
    D'Souza DC; Radhakrishnan R; Perry E; Bhakta S; Singh NM; Yadav R; Abi-Saab D; Pittman B; Chaturvedi SK; Sharma MP; Bell M; Andrade C
    Neuropsychopharmacology; 2013 Feb; 38(3):492-503. PubMed ID: 23093223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
    Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder.
    McClure MM; Graff F; Triebwasser J; Perez-Rodriguez M; Rosell DR; Koenigsberg H; Hazlett EA; Siever LJ; Harvey PD; New AS
    Am J Psychiatry; 2019 Apr; 176(4):307-314. PubMed ID: 30654644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
    Surti TS; Ranganathan M; Johannesen JK; Gueorguieva R; Deaso E; Kenney JG; Krystal JH; D'Souza DC
    Schizophr Res; 2023 Jun; 256():36-43. PubMed ID: 37141764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.
    Kruiper C; Sommer IEC; Koster M; Bakker PR; Durston S; Oranje B
    Schizophr Res; 2023 May; 255():148-154. PubMed ID: 36989672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of
    Goh KK; Wu TH; Chen CH; Lu ML
    J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia.
    Fisher M; Loewy R; Carter C; Lee A; Ragland JD; Niendam T; Schlosser D; Pham L; Miskovich T; Vinogradov S
    Schizophr Bull; 2015 Jan; 41(1):250-8. PubMed ID: 24444862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial.
    Correll CU; Potkin SG; Zhong Y; Harsányi J; Szatmári B; Earley W
    J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30695290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
    Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A
    J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.